1
|
Diker O, Aktas BY, Ak R, Koylu B, Bas O, Taban H, Guven DC, Olgun P, Kertmen N, Dizdar O, Oksuzoglu B, Aksoy S. Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience. Future Oncol 2021; 18:323-331. [PMID: 34758639 DOI: 10.2217/fon-2021-0303] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
Background: In node-negative HER2-overexpressed breast cancers, adjuvant paclitaxel plus trastuzumab treatment is a successful de-escalation approach with excellent survival outcomes. Methods: All patients with HER2+ breast cancer treated in our centers were retrospectively reviewed. Results: We analyzed 173 patients who were treated with adjuvant paclitaxel plus trastuzumab. The mean tumor size was 2.2 cm. There were eight invasive disease events or death: four distant recurrences (2.3%), three locoregional recurrences (1.7%) and one death without documented recurrence after a 52 month follow-up. The 3-year disease-free survival and recurrence-free interval rate was 96.6%. Conclusion: This real-life experience with adjuvant paclitaxel plus trastuzumab demonstrated few distant recurrences and is compatible with the APT trial findings.
Collapse
Affiliation(s)
- Omer Diker
- Department of Medical Oncology, Near East University, Faculty of Medicine, Nicosia, Cyprus
| | - Burak Yasin Aktas
- Department of Medical Oncology, Hacettepe University, Cancer Institute, Ankara, Turkey
| | - Recep Ak
- Department of Medical Oncology, Health Sciences University, Dr Abdurrahman Yurtaslan Ankara Oncology Training & Research Hospital, Ankara, Turkey
| | - Bahadır Koylu
- Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey
| | - Onur Bas
- Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey
| | - Hakan Taban
- Department of Medical Oncology, Hacettepe University, Cancer Institute, Ankara, Turkey
| | - Deniz Can Guven
- Department of Medical Oncology, Hacettepe University, Cancer Institute, Ankara, Turkey
| | - Polat Olgun
- Department of Medical Oncology, Near East University, Faculty of Medicine, Nicosia, Cyprus
| | - Neyran Kertmen
- Department of Medical Oncology, Hacettepe University, Cancer Institute, Ankara, Turkey
| | - Omer Dizdar
- Department of Medical Oncology, Hacettepe University, Cancer Institute, Ankara, Turkey
| | - Berna Oksuzoglu
- Department of Medical Oncology, Health Sciences University, Dr Abdurrahman Yurtaslan Ankara Oncology Training & Research Hospital, Ankara, Turkey
| | - Sercan Aksoy
- Department of Medical Oncology, Hacettepe University, Cancer Institute, Ankara, Turkey
| |
Collapse
|